Recent news on Cetrorelix

A New Era at AEterna  -  25 May 2007
Motley FoolLead hormone therapy products cetrorelix and ozarelix aim to compete with Lupron Depot (a product of TAP Pharma, the joint venture of Abbott Labs and

AEterna Zentaris Reports First Quarter 2007 Financial and ...  -  May 2, 2007
CNW Telbec (Communiqués de presse),Positive Phase 2a results in Japan with cetrorelix in BPH - The Company, along with its Japanese partner, Shionogi, announced positive results for a Phase

AEterna Zentaris Bolsters Management Team with Two Key Positions Named  -  May 7, 2007
CNW Telbec (Communiqués de presse),..."Nick's strong regulatory and drug development expertise is essential as we advance our Phase 3 program for cetrorelix in BPH, preparing for the expected

AEterna Zentaris Reports First Patients Treated with Cetrorelix ...  -  Apr 19, 2007
CNW Telbec (Communiqués de presse),As previously announced, the first study of the Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic

AEterna Zentaris Reports Positive Results with Cetrorelix in BPH ...  -  Mar 29, 2007
Drug Newswire (press release),Results showed that cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, was safe and well tolerated at all dosage

Æterna Zentaris Initiates First Study of Phase 3 Program with ...  -  Jan 9, 2007
PipelineReview.com (press release),The first study of the previously announced Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a

Aeterna Zentaris begins studies  -  Jan 9, 2007
Montreal Gazette (subscription),Aeterna Zentaris Inc. begins the first of three studies in Phase 3 trial for cetrorelix compound, used in treatment of abnormal benign growth of prostate.

AEterna starts Phase 3 study of prostate treatment  -  Jan 8, 2007
Reuters Canada,TORONTO (Reuters) - AEterna Zentaris said on Monday it began the first of three studies in its Phase 3 program of cetrorelix, its flagship treatment for

AEterna starts Phase 3 study of prostate treatment  -  Jan 8, 2007
Reuters Canada,TO: Quote) said on Monday it began the first of three studies in its Phase 3 program of cetrorelix, its flagship treatment for abnormal benign growth of

Pharma Sector : Few Newsmakers Of The Week - MedImmune, Shire Plc ...  -  Jan 13, 2007
Trading Markets,The company also initiated the first of three studies in its Phase 3 program with cetrorelix for patients with benign or noncancerous enlargement of the

Jump in oil prices helps send Toronto stocks higher, NY lower  -  Jan 8, 2007
Canada.com,...-Aeterna Zentaris Inc. (TSX:AEZ) shares rose eight cents to $4.60 after it began the first of three studies in a Phase 3 trial for its cetrorelix compound,

Gains on TSX deteriorate  -  Jan 8, 2007
Montreal Gazette,Aeterna Zentaris Inc. (TSX:AEZ) shares were unchanged at $4.52 after the firm began the first of three studies in a Phase 3 trial for its cetrorelix

Morning business file: Diamond find (9 am)  -  Jan 8, 2007
Edmonton Journal (subscription),Aeterna Zentaris Inc. (TSX:AEZ) shares rose five cents to $4.57 after the firm began the first of three studies in a Phase 3 trial for its cetrorelix

(PRN) - SnoCountry Reports Latest Skiing Conditions Information ...  -  Jan 8, 2007
Bolsamania.com,...(PRN) - AEterna Zentaris Initiates First Study of Phase 3 Program with Cetrorelix in BPH - 600 Patient Trial Conducted in the United States and Canada .

Æterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ...  -  Nov 30, 2006
PipelineReview.com (press release),Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year placebo-controlled efficacy study and long-term safety

AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH  -  Nov 29, 2006
CNW Telbec (Communiqués de presse),The first study of this Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year

UPDATE 1-AEterna to start cetrorelix Phase 3 by year-end  -  Nov 29, 2006
ReutersTO: Quote, Profile, Research) said on Wednesday it plans to initiate before year-end a Phase 3 trial for cetrorelix, a luteinizing hormone-releasing hormone

Market Report -- In Play (AEZS)  -  Nov 29, 2006
MSN MoneyAEterna Zentaris to initiate Phase 3 program with Cetrorelix in BPH Co announces its plan to initiate its Phase 3 program in benign prostatic hyperplasia

AEterna Zentaris (AEZS) to Initiate Phase 3 Program in Benign ...  -  Nov 29, 2006
StreetInsider.com (subscription),Patients will then be allocated to cetrorelix in a double-blind, randomized, double-dummy, placebo-controlled fashion. The primary efficacy endpoint of this

AEterna Zentaris to Webcast Analyst Meeting in Toronto on November ...  -  Nov 27, 2006
PharmaLive.com (press release),Company management and opinion leaders will present and discuss the development of its lead compounds cetrorelix, ozarelix and perifosine, as well as other

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,With the FDA accepting its initial new drug application of cetrorelix, AEterna Zentaris may well be on its way to penetrate a $4 billion plus market such as

Toronto stocks seen up with Bombardier, M&A fever  -  Nov 29, 2006
Reuters Canada,TO: Quote) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end. On the commodities front,

Toronto stocks seen up with Bombardier, M&A fever  -  Nov 29, 2006
ReutersTO: Quote, Profile, Research) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end.

(PRN) - Seagate Savvio Small Form Factor Enterprise Hard Drives ...  -  Nov 29, 2006
Bolsamania.com,...(PRN) - AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ... [+]. (PRN) - Archemix Grants Ribomic a License to its Intellectual Property

AEterna Zentaris Launches Cetrotide(R) (cetrorelix) in Japan for ...  Sep 21, 2006
...(TSX: AEZ - News; NASDAQ: AEZS - News) today announced that Cetrotide® (cetrorelix) has been launched in Japan for in vitro fertilization. ... -Yahoo! News

AEterna Zentaris Launches Cetrotide(R) (cetrorelix) in Japan for ...  Sep 21, 2006
...(TSX: AEZ; NASDAQ: AEZS) today announced that Cetrotide(R) (cetrorelix) has been launched in Japan for in vitro fertilization. Cetrotide ... -American Digital Networks

AEterna Zentaris Launches Cetrotide (cetrorelix) in Japan for In ...  Sep 21, 2006
...today announced that Cetrotide(R) (cetrorelix) has been launched in Japan for in vitro fertilization. Cetrotide(R) (cetrorelix) is ... -PharmaLive.com

Shionogi, Nippon Kayaku To Release Cetrotide In Japan  Sep 23, 2006
...and Nippon Kayaku Co., Ltd. today announced the release of Cetrotide (generic name: Cetrorelix acetate), indicated for the prevention of premature ovulation. ... -Medical News Today

Æterna Zentaris initiated with "buy"  Sep 18, 2006
...morning, the analysts mention that the company has a large pipeline of capable endocrinology and oncology drug candidates, such as Cetrorelix, Ozarelix and ... -newratings.com

AEterna Zentaris to Sell 3,485,000 Subordinate Voting Shares of ...  Sep 19, 2006
Moving forward, we remain committed to further invest in R&D and advance our promising lead product candidates, namely cetrorelix in BPH, while also advancing ... -CCNMatthews

Æterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ...  -  Nov 30, 2006
PipelineReview.com (press release),Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year placebo-controlled efficacy study and long-term safety

AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH  -  Nov 29, 2006
CNW Telbec (Communiqués de presse),The first study of this Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year

UPDATE 1-AEterna to start cetrorelix Phase 3 by year-end  -  Nov 29, 2006
ReutersTO: Quote, Profile, Research) said on Wednesday it plans to initiate before year-end a Phase 3 trial for cetrorelix, a luteinizing hormone-releasing hormone

Market Report -- In Play (AEZS)  -  Nov 29, 2006
MSN MoneyAEterna Zentaris to initiate Phase 3 program with Cetrorelix in BPH Co announces its plan to initiate its Phase 3 program in benign prostatic hyperplasia

AEterna Zentaris (AEZS) to Initiate Phase 3 Program in Benign ...  -  Nov 29, 2006
StreetInsider.com (subscription),Patients will then be allocated to cetrorelix in a double-blind, randomized, double-dummy, placebo-controlled fashion. The primary efficacy endpoint of this

Aeterna Zentaris Reports 2006 Third Quarter Results  -  Nov 13, 2006
CNW Telbec (Communiqués de presse),Additionally, we launched the first LHRH antagonist to enter the Japanese market, Cetrotide(R) (cetrorelix) for in vitro fertilization with our Japanese

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,With the FDA accepting its initial new drug application of cetrorelix, AEterna Zentaris may well be on its way to penetrate a $4 billion plus market such as

AEterna Zentaris to Webcast Analyst Meeting in Toronto on November ...  -  Nov 27, 2006
PharmaLive.com (press release),Company management and opinion leaders will present and discuss the development of its lead compounds cetrorelix, ozarelix and perifosine, as well as other

Toronto stocks seen up with Bombardier, M&A fever  -  Nov 29, 2006
Reuters Canada,TO: Quote) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end. On the commodities front,

Toronto stocks seen up with Bombardier, M&A fever  -  Nov 29, 2006
ReutersTO: Quote, Profile, Research) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end.

(PRN) - Seagate Savvio Small Form Factor Enterprise Hard Drives ...  -  Nov 29, 2006
Bolsamania.com,...(PRN) - AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ... [+]. (PRN) - Archemix Grants Ribomic a License to its Intellectual Property

AEterna Zentaris Reports 2006 Second Quarter Results  Aug 11, 2006
Japan, our successful meeting with the FDA leading to the upcoming filing of an IND to move forward into Phase 3 clinical development of cetrorelix in benign ... -MSN Money

AEterna to submit cetrorelix new drug application  Jun 21, 2006
...on Wednesday it plans to submit an investigational new drug application to the US Food & Drug Administration to start a Phase 3 program for cetrorelix in the ... -Metro Toronto

AEterna Zentaris Receives Green Light from FDA to Move Forward ...  Jun 21, 2006
...of Phase 2 meeting, the US Food & Drug Administration (FDA) reviewed the safety and efficacy data from an extensive Phase 2 program with cetrorelix, its lead ... -Canada NewsWire

AEterna Zentaris Receives Green Light from FDA to Move Forward ...  Jun 21, 2006
...cetrorelix in BPH. "We ... development of cetrorelix in BPH with a Phase 3 program," commented Dr. Jurgen. AEterna Zentaris. "Cetrorelix ... -Les Affaires (Communiqués de presse)

AEterna Zentaris to File for FDA Trial  Jun 21, 2006
...it plans to submit an application with the Food and Drug Administration to begin a late-stage clinical trial for its enlarged prostate treatment, Cetrorelix. ... -MSN Money

AEterna to submit new drug application shortly  Jun 21, 2006
Wednesday it plans to submit an investigational new drug application to the US Food & Drug Administration for the initiation of a Phase 3 program for cetrorelix ... -Reuters

Direct Effect of Progestogen on Gene Expression in the Testis ...  Jul 6, 2006
Interventions: Subjects were randomized to no treatment or gonadotropin suppression by GnRH antagonist (cetrorelix) with testosterone (CT group) or with ... -Journal of Clinical Endocrinology and Metabolism

AEterna Zentaris Reports Positive In Vivo Data On ZEN-019 - Update  Jun 27, 2006
The Company's two lead products in this therapeutic approach are: cetrorelix, marketed for in vitro fertilization under the brand name Cetrotide and in late ... -Trading Markets

(PRN) - The First American Corporation Expands Title Operations In ...  Jun 21, 2006
Expansion ... [+. PRN) - AEterna Zentaris Receives Green Light from FDA to Move Forward into Phase 3 Program with Cetrorelix in BPH ... [+. ... -Bolsamania.com

AEterna Zentaris Presented Positive In Vivo Data on ZEN-019, an ...  Jun 27, 2006
The Company's two lead products in this therapeutic approach are: cetrorelix, marketed for in vitro fertilization under the brand name Cetrotide® and in late ... -Yahoo! News

AEterna Zentaris Reports 2006 First Quarter Financial and ...  May 3, 2006
Furthermore, we were very pleased to have regained the worldwide, ex-Japan rights for cetrorelix in BPH, and are presently in the process of designing a ... - PharmaLive.com

Preventing Premature Ovulation - Shionogi, Nippon Kayaku Receive ...  Apr 23, 2006
Cetrotide (cetrorelix acetate), which was developed by German company Zentaris AG, is currently available in 92 countries worldwide. ... - Medical News Today



AEterna Zentaris Gains Market Approval for Cetrotide (cetrorelix) ...  Apr 20, 2006
...today announced it gained market approval for Cetrotide® (cetrorelix) in Japan for in vitro fertilization. Cetrotide (cetrorelix ... - DG News

AEterna Zentaris Gains Market Approval for Cetrotide(R) ...  Apr 20, 2006
...(TSX: AEZ; NASDAQ: AEZS) today announced it gained market approval for Cetrotide(R) (cetrorelix) in Japan for in vitro fertilization. ... - PR Newswire

AEterna Zentaris Gains Market Approval for Cetrotide(R) ...  Apr 20, 2006
Cetrotide(R) (cetrorelix) has been marketed worldwide (ex-Japan) by. ... "We are very pleased that Cetrotide(R) (cetrorelix) has been approved for. ... - Les Affaires (Communiqués de presse)

AEterna Zentaris Reports 2006 First Quarter Financial and ...  May 3, 2006
...tubulin inhibitors, signal transduction inhibitors and cytotoxic conjugates; and - Regained the exclusive worldwide (ex-Japan) rights for cetrorelix in benign ... - Yahoo! News

International Approvals: Omnitrope, Prograf, Cetrotide  May 1, 2006
Japan's Ministry of Health, Labor, and Welfare has approved cetrorelix acetate injection for preventing premature ovulation in women undergoing ovarian ... - Medscape (subscription)

AEterna Zentaris Reports 2006 First Quarter Financial and ...  May 3, 2006
Furthermore, we were very pleased to have regained the worldwide, ex-Japan rights for cetrorelix in BPH, and are presently in the process of designing a ... - PharmaLive.com

Preventing Premature Ovulation - Shionogi, Nippon Kayaku Receive ...  Apr 23, 2006
Cetrotide (cetrorelix acetate), which was developed by German company Zentaris AG, is currently available in 92 countries worldwide. ... - Medical News Today

AEterna Zentaris Reports 2005 Fourth Quarter and Full-Year ...  Mar 1, 2006
Product Development Pipeline Advancements - Cetrorelix: Initiation of pivotal clinical program in endometriosis by partner, Solvay and Phase 2 trial in benign ... - MSN Money

AEterna Zentaris swings to Q4 profit of US$936K from year-ago $2M ...  Mar 1, 2006
..."Over the past year, we made great strides in advancing our lead product development candidates, cetrorelix, ozarelix and perifosine through the pipeline ... - CBC News,

Aeterna regains global rights to cetrorelix  Jan 31, 2006
...and its partner Solvay Pharmaceuticals have reached an agreement whereby Aeterna will regain exclusive global rights to its cetrorelix product, without any ... - Pharmaceutical Business Review

AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for ...  Jan 30, 2006
...regains exclusive worldwide (ex-Japan) rights on its lead Luteinizing Hormone Releasing Hormone (LHRH) antagonist product candidate, cetrorelix for the benign ... - Canada NewsWire

(PRN) - Sanmina-SCI Revises Stock Compensation Expenses and Issues ...  Jan 30, 2006
...[+]. (PRN) - AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia ... [+. ... - Bolsamania.com

AEterna Zentaris appoints former Abbott Vice President to its ...  Jan 25, 2006
This will surely be a great asset in the development of our own products, cetrorelix and ozarelix, currently being studied in benign prostatic hyperplasia and ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional